Cellular therapy offers promise for patients with late-stage Duchenne muscular dystrophy (DMD), a rare genetic disorder causing muscle loss and physical impairments in young people. Findings from the HOPE-2 clinical trial were published in @TheLancet today. 1/2 pic.twitter.com/xdyBj3ZXKV

— UCDavisChildrensHosp (@UCDavisChildren) March 11, 2022